Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension

John D Bisognano¹
Trent McLaughlin²
Craig S Roberts³
Simon SK Tang³

¹Internal Medicine Department, Cardiology Division, the University of Rochester Medical Center, Rochester, NY, USA; ²NDC Health, Phoenix, Arizona, USA; ³Pfizer Inc, New York, NY, USA

Abstract: This retrospective database analysis compared the effectiveness of dihydropyridine calcium channel blockers (DHPs), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) added to diuretics or β-blockers. Adults with hypertension treated with diuretic or β-blocker monotherapy between 1998 and 2001 were identified from a large US electronic medical records database of primary care practices. Patients were required to have a baseline blood pressure (BP) ≥140/90 mmHg (≥130/80 mmHg for diabetes mellitus) and recorded BP measurements within 6 months before and 1–12 months following index date. Patients were matched 1:1:1 by propensity score to correct for differences in baseline characteristics. 1875 patients met study criteria and 660 (220 in each cohort) were matched based on propensity scores. Matched cohorts had no significant differences in baseline characteristics. Mean changes in systolic/diastolic BP were −17.5/−8.8, −15.7/−6.3, and −13.0/−8.0 mmHg with DHPs, ACE inhibitors, and ARBs, respectively. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High BP 6/7 goal attainment for each regimen was 47.3%, 40.0%, and 32.2%, respectively. DHPs, ACE inhibitors, and ARBs improved BP when added to patients’ β-blocker or diuretic therapy. The greatest benefits were observed with DHPs, followed by ACE inhibitors, then ARBs.

Keywords: hypertension, amlodipine besylate, lisinopril, valsartan, Joint National Committee (JNC) 6 and 7

Introduction

Hypertension is a key independent risk factor for cardiovascular diseases (CVD), such as heart failure, stroke, coronary heart disease (CHD), and end-stage renal disease (Chobanian et al 2003).

Morbidity and mortality from hypertension-associated disease have been reduced in the US over the past three decades (Chobanian et al 2003). However, past progress has not been maintained. The prevalence of hypertension in the US has increased recently (Hajjar and Kotchen 2003). Death rates from CHD and stroke have failed to further improve, and end-stage renal disease is being diagnosed at increasing rates (Chobanian et al 2003). Importantly, more than two thirds of hypertensive adults in the US do not have their BP under control, manifesting BP levels ≥140/90 mmHg (Chobanian et al 2003; Hajjar and Kotchen 2003).

The Sixth Report of the Joint National Committee (JNC) on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 6) recommended initiation of antihypertensive therapy using a diuretic or β-blocker for patients who have no specific indications for other drug classes (Joint National Committee 1997). The sub-
sequent JNC 7 guidelines recommended thiazide diuretics as the preferred initial agent (Chobanian et al 2003). However, approximately half of patients treated for hypertension do not respond to monotherapy (Materson et al 1993). Indeed, large landmark clinical trials have shown that patients often require up to four medications to achieve BP control (Hansson et al 1998; ALLHAT Collaborative Research Group 2002; Dahlof et al 2002; Black et al 2003). It is now accepted that in order to achieve BP goals, most patients will require at least two antihypertensive agents, each from a different class, including diuretics, β-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and dihydropyridine calcium channel blockers (DHPs) (Bakris 2001; American Diabetes Association 2002; Chobanian et al 2003; Guidelines Committee 2003).

Despite support for the use of multiple therapies in treating hypertension, few studies have compared the effectiveness of different antihypertensive classes and agents as part of a multidrug regimen in real-world clinical practice. Many real-world issues, such as suboptimal patient adherence with medications, are often not accounted for in clinical trials (Monane et al 1997; Burnier et al 2001). The objective of this retrospective cohort analysis was to compare, within a physician office setting, the clinical effectiveness of DHPs, ACE inhibitors, and ARBs when added to diuretic or β-blocker therapy in patients who had previously received a diuretic or β-blocker, but had failed to achieve their BP goal. This study compared the effectiveness of different multiple antihypertensive regimens used in a way that mirrored the JNC 6 treatment recommendations that were in effect during the time period of the study cohort. Clinical effectiveness was measured by absolute BP reductions as well as by attainment of BP goals specified by key treatment guidelines, including both JNC 6 and 7.

Methods
Data source
This retrospective database analysis used encrypted data extracted from the GE Medical Quality Improvement Consortium Electronic Medical Records (EMR) database. At the time of this analysis, the database contained longitudinal data for approximately 370,000 patients who were receiving treatment from primary care physicians across the US. Data collected from patient records included demographics and diagnoses, prescribed medications and procedures, cardiac risk factors, test results, and patient functional status. Physicians were from large practices in Oregon, Arizona, Texas, Massachusetts, Iowa, Virginia, New Hampshire, and Maine who had been using the EMR database for at least 1 year at study initiation.

Study population
Patients aged ≥20 years who visited a physician’s office during a 4-year period (1998 through 2001), had a documented diagnosis of hypertension (ICD-9-CM: 401.xx) and/or “hypertension/high BP” documented in the problem list, and initiated add-on treatment with any ACE inhibitor, ARB, or DHP were identified for the study. Add-on therapy was operationally defined as patients already receiving β-blocker or diuretic therapy at the time the ACE, ARB, or DHP was initiated; therefore, all study patients were required to be receiving prior treatment with a β-blocker or diuretic. Those patients receiving ACE inhibitor/diuretic or ARB/diuretic fixed-dose combinations were included only if they previously used a diuretic and had discontinued the diuretic at the time the fixed-dose combination was initiated.

At least two valid BP readings (pre- and post-index) were required for each patient. The pre-index (or baseline) BP reading, defined as the most recent measurement within 6 months before the initiation of ACE inhibitor, ARB, or DHP therapy, was required to be ≥140/90 mmHg for patients who did not have diabetes and ≥130/80 mmHg for patients with diabetes mellitus. The post-index measurement was the final BP reading between 1 to 12 months following the index date and must have been taken before the earliest of the following events: discontinuation of the ACE inhibitor, ARB, or DHP; initiation of any other antihypertensive agent; or 12 months after initiation of the ACE inhibitor, ARB, or DHP. Consequently, patients who initiated another antihypertensive agent on the same day or within the first month of initiating the index ACE inhibitor, ARB, or DHP were excluded, as were patients who discontinued their index product within 1 month of its initiation. Patients also were excluded if they had a recorded diagnosis of congestive heart failure or previous treatment with any other antihypertensive agent. The time frame for the study is depicted in Figure 1.

Data collection
Patient demographics at baseline included age, sex, and weight. During the study period, a number of data were collected to enable comparison of disease severity between patient groups. These data included patients’ age, comorbid hyperlipidemia, diabetes, coronary artery disease and/or, end-stage renal disease, baseline SBP and DBP, and JNC 6 BP stage, the number of BP measurements during the 6 months prior to ACE inhibitor, ARB, or DHP initiation,
month/year of ACE inhibitor, ARB, or DHP initiation, prior therapy (β-blocker versus diuretic), and interval between baseline BP measurement and the date of ACE inhibitor, ARB, or DHP initiation. Additionally, Charlson’s comorbidity index, a single score based on the sum of a weighted ranking of comorbid conditions, was calculated from patient data at baseline in order to compare the overall health status of patient groups (Charlson et al 1987). The calculations were based on ICD-9 codes, using the methods described by Romano et al (1993).

As data were analyzed for patients receiving treatment during the period 1998 through 2001, BP goal attainment was defined by JNC 6 (Joint National Committee 1997), the JNC 6 goals were incorporated into the newer JNC 7 guidelines after the study period (Chobanian et al 2003). Therefore, JNC 6/7 BP goal attainment was calculated as the proportion of patients with a final BP reading <140/90 mmHg. Attainment of the American Diabetes Association (ADA) goal for hypertension was also calculated, and was defined as the proportion of patients with BP <130/80 mmHg (American Diabetes Association 2002).

Statistical analyses
To reduce the potential influence of confounding variables, a statistical matching technique was utilized. Propensity scores (D’Agostino 1998) were calculated as the probability of being in the DHP and ACE inhibitor cohorts using a multinomial logistic regression model. Patients across the three study cohorts (ACE inhibitor, ARB, DHP) were matched using propensity scores at a 1:1:1 ratio. A set of three matches was identified as the first three patients selected in random order who matched on the likelihood of being in the DHP and ACE inhibitor groups within one-fourth standard deviation of the respective propensity scores. This matching process continued until there were no more sets of three matching patients. One of the advantages of this technique over the use of Cox proportional hazard models is that it removes differences between the groups where attributes of one treatment group may be completely absent in other treatment groups. In retrospective data where treatment assignment is very systematic, these differences can impact the regression model and cause under/over correction for data within the common sample subjects, due to the influence of an unlike group in one arm.

The main study outcomes were incremental mean change in SBP and DBP from pre- to post-index BP reading and the percentage of patients reaching BP goals according to JNC 6/7. Categoric variables were presented as the sum and percentage of patients, and continuous variables as the mean and standard deviation. Baseline characteristics and treatment outcomes were compared using a chi-square test and analysis of variance (ANOVA) for categorical and continuous variables, respectively. Baseline characteristics were tested despite the scoring matching technique used, because matching was based on the p-score, and not each individual characteristic that was used to generate the p-score. Therefore, it was still possible that some differences could exist between the groups with respect to some characteristics. This process also served to test how successful the propensity matching had been. No corrections were applied to p-values for multiple comparisons. Analyses were performed using SAS version 8.2 (SAS Institute, SAS Procedures Guide, Version 8.2, 2002; SAS Institute, Cary, NC, USA).

Results
Baseline characteristics
A total of 1875 patients met the original inclusion criteria for the study; after applying propensity score matching, a total of 660 (220 for each cohort) were included in the final analysis (Table 1). There were no statistically significant differences between the DHP, ACE inhibitor, and ARB groups at baseline for mean age, percentage of male patients, and pre-index SBP or DBP. Within medication classes, the most commonly used agents were: DHP (amlodipine besylate [81%]); ACE inhibitor (lisinopril [52%]); ARB (valsartan [50%]). The mean intervals between starting and ending BP measurements were 256 days (DHP), 261 days (ACE inhibitor), and 265 days (ARB). There were no statistically significant differences between the cohorts with respect to the measurement intervals.
Blood pressure outcomes

As shown in Figure 2, mean (SD) SBP reductions in the overall sample were –17.5 (21.0) mmHg for patients receiving add-on DHP therapy, –15.7 (20.2) mmHg for those receiving ACE inhibitors as add-on therapy, and –13.0 (21.4) mmHg among patients that received add-on treatment with anARB. The reductions in SBP were slightly greater when DHP or ACE inhibitors were added on to patients receiving β-blockers in comparison to when they were used as additional therapy in those receiving diuretics as initial therapy, whereas the converse was true for ARBs.

Figure 3 shows that overall mean (SD) reductions in DBP in patients who received DHP as add-on therapy were –8.8 (12.7) mmHg in comparison with –6.3 (11.4) mmHg for those receiving add-on ACE inhibitor therapy, and –8.0 (12.2) mmHg in those that received add-on ARBs.

Reductions in DBP were slightly greater when ACE inhibitors or ARBs were added on to patients receiving initial therapy with diuretics versus those receiving β-blockers as initial therapy. In contrast to this, reductions in DBP with DHP add-on therapy were greater in those on initial therapy with β-blockers versus diuretics.

Blood pressure goal attainment is illustrated in Figure 4. As shown, 47.3% of study patients in the overall DHP-cohort achieved the JNC 6/7 BP goals during the year following treatment initiation, in comparison with 40.0% in the ACE inhibitor group and 32.2% of those receiving add-on therapy with β-blockers. Much of this difference appeared due to improved performance among the cohort initially receiving β-blockers, for whom goal attainment with the addition of DHPs was 52.0% and with the addition of ACE inhibitors it was 43.4% versus 30.4% for ARBs.

Discussion

This “real-world” analysis supports the use of combinations of antihypertensive drugs in order to reduce SBP and DBP and to enable patients to achieve JNC 6/7 BP goals. The addition of an ACE inhibitor, ARB, or DHP to existing β-blocker or diuretic treatment for up to 12 months resulted in significant reductions in SBP and DBP compared with baseline values. These results are in agreement with findings from clinical trials showing that more than one antihypertensive drug is often required to reduce BP and achieve BP control (Hansson et al 1998; ALLHAT Collaborative Research Group 2002; Dahlöf et al 2002; Black et al 2003). The mean reduction in BP during the study period reported here ranged from 13.0 mmHg to 17.5 mmHg for SBP, and from 6.3 mmHg to 8.8 mmHg for DBP. Sustained BP reductions of this magnitude in patients with hypertension are likely to represent a clinically meaningful treatment effect (Staessen et al 2003; Turnbull et al 2005).

When comparing the effects of three different antihypertensive drug classes as add-ons to β-blocker or diuretic therapy, DHPs were associated with the greatest improvements in BP, followed by ACE inhibitors and then ARBs. We observed that SBP was reduced to a statistically greater extent by DHPs compared with ARBs. Large-scale clinical trials have confirmed that DHP-based treatment regimens are associated with reduced cardiovascular events compared with β-blocker-based therapy (Dahlöf et al 2005) and similar reductions to ARB-based antihypertensive regimens (Julius et al 2004). The benefits of ACE inhibitor or DHP combination therapy on SBP is significant, given the importance of SBP as a major risk factor for CVD and the difficulty of

Table 1 Propensity score matching – baseline characteristics

| Patients (n = 660) | DHP (n = 220) | ACE (n = 220) | ARB (n = 220) |
|-------------------|--------------|--------------|--------------|
| Mean age (SD)     | 65.6 (14.8)  | 65.6 (13.7)  | 66.1 (14.8)  |
| Male (%)          | 66.8         | 68.6         | 67.1         |
| Diuretic versus β-blocker (%) | 62.7 | 61.4 | 60.9 |
| Charlson Index    | 0.88 (1.4)   | 0.83 (1.3)   | 0.92 (1.5)   |
| Diabetes (%)      | 45.9         | 47.7         | 47.7         |
| CAD (%)           | 12.2         | 13.2         | 11.4         |
| Pre-index SBP mean (SD) (mmHg) | 156.1 (17.5) | 154.9 (16.3) | 155.6 (18.4) |
| Pre-index DBP mean (SD) (mmHg) | 88.5 (11.7)  | 87.9 (10.7)  | 88.4 (12.6)  |

Abbreviations: DHP, dihydropyridine calcium channel blocker; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; SD, standard deviation; CAD, coronary artery disease; SBP, systolic blood pressure; DBP, diastolic blood pressure.
achieving improvement in this measure (Izzo et al 2000; Chobanian et al 2003). When given in combination with β-blockers or diuretics, DHPs also resulted in a significantly greater reduction in DBP compared with that achieved with ACE inhibitors.

Overall, JNC 6/7 BP goal was achieved by up to 47% of patients taking combination therapy in this analysis. However, a greater proportion of patients attained BP goal when either a DHP (47.3%) or an ACE inhibitor (40.0%) was added to pre-existing β-blocker or diuretic therapy, compared with patients receiving an ARB (32.2%) as add-on therapy. Our study used a standard definition of hypertension control based on the JNC 6 guidelines, as these were applicable during the period for which the data were analyzed (1998 through 2001). The recommendations of JNC 6 have been incorporated into JNC 7; thus, the outcomes of this study continue to be relevant. Nevertheless, 50% of patients in this study had not achieved their BP goal with two agents, suggesting that either the dose of these agents should have been increased further or that additional agents should have been added. Indeed, the Irbesartan type II Diabetic Neuropathy Trials showed more than three antihypertensive agents were required to control BP (Lewis et al 2001).

Although our analysis does not report results for specific antihypertensive agents, patient drug therapies were reported. The majority of patients taking DHPs (81%) in the study received amlodipine besylate, and approximately half the patients taking ACE inhibitors and ARBs took lisinopril and valsartan, respectively. We recently performed a retrospective database analysis that specifically assessed the clinical effectiveness of amiodipine given as monotherapy or in combination with other antihypertensive drugs in reducing BP and attaining BP goals (Bisognano et al 2004). There were substantial reductions in BP when amlodipine was added to antihypertensive regimens. The benefits occurred regardless of the number of antihypertensive drugs that patients were taking upon initiation of amiodipine (Bisognano et al 2004). The observations from the present study corroborate those from our earlier study.

The study reported here has some limitations. Firstly, the results are based on patient samples from several large US general physician practices and may not be generalizable to other populations treated by other physicians. Results may not be applicable to practices without electronic medical records. Secondly, patient adherence to medication regimens was not documented. Low rates of adherence or patient discontinuation of therapy may affect outcomes with medications, and the impact of this effect cannot be taken into account in this analysis. However, discontinuations and lack of adherence are realities of real-world treatment, and while they may limit evaluation of pure efficacy from the study, incorporation of these factors may better reflect real-world effectiveness. Thirdly, JNC 6 states that if a diuretic is not used as the initial antihypertensive it is usually indicated as the second agent because its addition will enhance the effects of other agents. Therefore, the use of DHPs, ACE inhibitors, and ARBs of add-on therapy in patients receiving β-blockers as initial therapy suggests poor compliance with this recommendation. Fourthly, sample sizes in the present study were small and did not allow analysis of results for key subpopulations (for example, the elderly and patients with diabetes mellitus). The propensity matching technique used also reduced the sample size. However, the intent was to compare similar cohorts (based on baseline characteristics) and this was thought more important than keeping all patients.

![Figure 3 Incremental diastolic blood pressure reduction. *p < 0.05 versus DHP. Abbreviations: DHP, dihydropyridine calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure.](image1)

![Figure 4 JNC 6/7 BP goal attainment. *p < 0.05 versus DHP. Abbreviations: DHP, dihydropyridine calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.](image2)
in the sample. Finally, the use of a single pre- and post-index measurement of BP is a limitation. The single pre- and post-index measurement was a prospectively defined end point for this analysis based on application of this end point in a prior study (Bisognano et al 2004). Alternative definitions may provide differing results, however we felt this definition was the most consistent measure between patients based on the structure of the database, and the fairest end point to compare across treatment groups.

Another potential limitation of this analysis is that channeling bias (Petri and Urquhart 1991) may not be fully addressed, although propensity matching analyses (D’Agostino 1998) were performed to address between-group differences in a number of baseline characteristics. Channeling bias may occur in observational studies because prescribing does not occur by random allocation in clinical practice, in contrast to randomized controlled trials where treatment assignment is random. As it was not known why the prescribing physicians decided upon the use of each antihypertensive agent, whether as initial or subsequent therapy, we cannot fully assess whether patient or prescriber factors systematically led to different treatment choices for different patient types. To the extent that these patient factors were collected and incorporated into the propensity score model, this effect is largely accounted for. However, these treatment choices may have been driven by unobserved factors, such as perceptions of or reaction to indications or formulary restrictions. However, collecting and correcting for such factors were beyond the scope of this study.

Although retrospective cohort analyses such as the study reported here have traditionally been considered to have limited use in comparing treatments, there is evidence that such observational studies and randomized controlled trials demonstrate similar treatment effects (Benson and Hartz 2000; Concato et al 2000). Therefore, despite limitations, most of which are inherent in observational studies, this report provides important results of treatment outcomes in a physician office setting.

In summary, our findings support the benefits of adding a second antihypertensive agent to a patient’s antihypertensive treatment regimen. The greatest benefits are observed when DHPs, followed by ACE inhibitors, and then ARBs are added as second-line therapy to patients already on β-blocker or diuretic therapies. Naturally, if patients have specific indications for specific drug treatment (such as proteinuria or diabetes), such indications must be followed. These findings suggest that appropriate and early integration of an additional antihypertensive drug into patients’ therapeutic regimens, particularly a DHP, together with the appropriate dose titration may lead to improved BP outcomes in real-world clinical practice.

### Conflicts of interest

Funding for this study was provided by the Pfizer Inc, Outcomes Research Group. Editorial assistance was provided by Jon Edwards of Envision Pharma and funded by Pfizer Inc.

Conflicts of Interest at the time the paper was written, Dr Trent McLaughlin was a paid employee of NDC Health; a firm that received funding from Pfizer Inc to conduct the analysis described in this paper. Drs Roberts and Tang are employees of Pfizer Inc, Dr Bisognano is on the Pfizer speaker’s bureau and received consultancy fees from Pfizer.

### References

ALLHAT Collaborative Research Group. 2002. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288:2981–97.

American Diabetes Association. 2002. Treatment of hypertension in adults with diabetes. Diabetes Care, 25:199–201.

Bakris GL. 2001. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med, 161:2661–7.

Benson K, Hartz AJ. 2000. A comparison of observational studies and randomized, controlled trials. Am J Ophthalmol, 130:688.

Bisognano J, McLaughlin T, Roberts CS, et al. 2004. Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. Am J Hypertens, 17:676–83.

Black HR, Elliott WJ, Grandits G, et al. 2003. Principal results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA, 289:2073–82.

Burnier M, Schneider MP, Chiolerio A, et al. 2001. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens, 19:335–41.

Charlson ME, Pompei P, Ales KL, et al. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 40:373–83.

Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206–52.

Concato J, Shah N, Horwitz RI. 2000. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med, 342:1887–92.

D’Agostino RB Jr. 1998. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med, 17:2265–81.

Dahlöf B, Devereux RB, Kjeldsen SE, et al. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359:995–1003.

Dahlöf B, Sever PS, Poulter NR, et al. 2005. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366:895–906.

Guidelines Committee. 2003. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, 21:1011–53.
Add-on therapy for hypertension

Hajjar I, Kotchen TA. 2003. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. *JAMA*, 290:199–206.

Hansson L, Zanchetti A, Carruthers SG, et al. 1998. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*, 351:1755–62.

Izzo JL Jr, Levy D, Black HR. 2000. Clinical Advisory Statement. Importance of systolic blood pressure in older Americans. *Hypertension*, 35:1021–4.

Joint National Committee on, Detection, Evaluation, and Treatment of High Blood Pressure. 1997. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med*, 157:2413–46.

Julius S, Kjeldsen SE, Weber M, et al. 2004. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. *Lancet*, 363:2022–31.

Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med*, 345:851–60.

Materson BJ, Reda DJ, Cushman WC, et al. 1993. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *N Engl J Med*, 328:914–21.

Monane M, Bohn RL, Gurwitz JH, et al. 1997. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. *Am J Hypertens*, 10:697–704.

Petri H, Urquhart J. 1991. Channeling bias in the interpretation of drug effects. *Stat Med*, 10:577–81.

Romano PS, Roos LL, Jollis JG. 1993. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. *J Clin Epidemiol*, 46:1075–97.

Staessen JA, Wang JG, Thijs L. 2003. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. *J Hypertens*, 21:1055–76.

Turnbull F, Neal B, Algert C, et al. 2005. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med*, 165:1410–19.
